IONS — Ionis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $7.33bn
- $7.19bn
- $943.71m
Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose (updated)
US FDA approves Ionis Pharma's therapy to treat rare genetic disorder
Ultragenyx hits record low after rare disease drug trial failure
Ultragenyx Pharma plunges after rare disease drug trial failure
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Alnylam, Ionis fall as heart-drug data raise doubts over combination treatment
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Ionis Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Ionis Q2 adjusted operating loss narrows
Arrowhead rises after blood-fat drug meets late-stage trial goals
U.S. RESEARCH ROUNDUP-BlackRock, Pennant Group, Weyerhaeuser Co
U.S. STOCKS ON THE MOVE-Natera, nLIGHT, Micron
U.S. STOCKS ON THE MOVE-Natera, nLIGHT, Forte Biosciences
U.S. STOCKS ON THE MOVE-Levi's, Meta, PepsiCo
U.S. STOCKS ON THE MOVE-Levi, Ionis Pharmaceuticals, Gloo Holdings
Ionis falls after AstraZeneca-partnered drug fails late-stage heart disease trial
AstraZeneca top loser on FTSE 100 after heart disease drug fails late-stage trial